Studies in rheumatoid arthritis have shown that biologic therapies targeting these cytokines can significantly alter body composition: IL-6 inhibition with tocilizumab has been associated with increases in lean mass and favorable metabolic shifts, whereas anti-TNF therapy has demonstrated improvements in muscle mass and density in some cohorts (13). Here, IL6 is linked to rheumatoid arthritis.